Format

Send to

Choose Destination
Clin Med (Lond). 2013 Aug;13(4):353-7. doi: 10.7861/clinmedicine.13-4-353.

Evidence underlying the clinical management of diabetic macular oedema.

Author information

1
Belfast Health and Social Care Trust, UK. mwilliams11@qub.ac.uk

Abstract

Diabetic retinopathy (DR) is the leading cause of visual loss in the developed world in those of working age, and its prevalence is predicted to double by 2025. The management of diabetic retinopathy has traditionally relied on screening, on laser treatment delivered by ophthalmologists, and on optimising blood glucose and blood pressure. Recent evidence suggests that the role of systemic factors is more complex than originally thought, and that drugs such as ACE inhibitors, fibrates and glitazones may all influence the course of diabetic macular oedema. Antagonism of vascular endothelial growth factor offers a new therapeutic avenue that may transform the management of diabetic macular oedema. Several other therapeutic options are under investigation and development, including aminoguanidine, sorbinol, ruboxistaurin and autologous stem cell transfusion.

KEYWORDS:

Retinopathy; diabetes; macular

PMID:
23908503
PMCID:
PMC4954300
DOI:
10.7861/clinmedicine.13-4-353
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center